Figure 4From: The siRNA targeted to mdr1b and mdr1a mRNAs in vivosensitizes murine lymphosarcoma to chemotherapy The dynamics of tumor development in mice after ex vivo and in vivo successive treatment with siRNA and cytostatics. (A) RLS40-bearing animals: wt, control mice bearing wild type tumor; luc siRNA, the mice bearing tumor cells transfected ex vivo with control luciferase siRNA; and mdr1b/1a siRNA, the mice bearing tumor cells transfected ex vivo with mdr1b/1a siRNA; (+CP) the animals treated with cyclophosphamide (100 mg/kg) on days 2 and 4 after tumor transplantation and (-CP) the animals without chemotherapeutic treatment. (B) RLS-bearing animals: wt, the control animals bearing wild type tumor; luc siRNA, the mice bearing tumor cells transfected ex vivo with control luciferase siRNA; and bcl-2 siRNA, the mice bearing tumor cells transfected ex vivo with bcl-2 siRNA; (+CP) the animals treated with cyclophosphamide (200 mg/kg) on day 2 after tumor transplantation and (-CP) the animals without chemotherapeutic treatment. (C) RLS40-bearing animals: luc siRNA, the mice with tumors transfected in vivo with luciferase siRNA and mdr1b/1a siRNA, the mice with tumors transfected in vivo with mdr1b/1a siRNA; (-) the animals without chemotherapeutic treatment, (+E) the animals treated with embichin (2 mg/kg) or (+CP) cyclophosphamide (200 mg/kg) on day 2 after tumor transplantation. ** p < 0.01, compared with cytostatic treatment; ## and ###, p < 0.01 and p < 0.001, respectively, compared with wt (A) or -/luc siRNA and -/mdr1b/1a siRNA (C).Back to article page